Is the Scancell share price set to rocket in 2023?

The Scancell share price has more than doubled in under two months. Our writer considers whether it can keep soaring in 2023 — and if he should invest.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

So far, 2022 has been a rewarding year for shareholders in Scancell (LSE: SCLP). The Scancell share price has increased by 34%.

But interestingly, that has been driven by the shares more than doubling since around the middle of October. Until that point, the shares had been around 37% down on the year.

Looking at that chart, clearly the shares have been on a tear lately. Could that very strong positive momentum continue in 2023 – and should I load up now in anticipation?

Promising news

There are several reasons for the recent surge in the Scancell share price.

In October, the company announced that it had licensed its technology to US biotech company Genmab, which specialises in cancer antibody therapies. It also announced its annual results, with losses falling from £15.4m the prior year to £2.1m last year.

The deal with Genmab could help to validate Scancell’s technology. That could be good for the Scancell share price in the long term.

I also think a much smaller loss is good news. Having said that, the fall was driven by financing-related costs. An operating loss of £8.8m the prior year actually rose to £13.3m last year, driven by higher expenditures on both development and administration.

This is also a good example of why as an investor one needs to look at cash flows, not only earnings. While the loss was £2.1m, the company ended its financial year with £12.4m less in cash than it started with.

How to value Scancell

Scancell has a market capitalisation of over £200m. What is it worth?

One thing missing from last year’s results was revenue. Scancell does not generate meaningful revenue at the moment, while its drugs are in a development phase. It has also been heavily loss-making for many years in a row.

So, clearly, investors are not valuing this growth company based on its current business performance. Instead, they are trying to estimate the potential value of the company’s drug portfolio if Scancell is able to bring them to market successfully, either on its own or by licensing them out.

How can we know whether a company’s vaccines or antibodies are effective? The ultimate answer lies in looking at the results of clinical trials. But Scancell is still at this trial stage. I therefore think it is unclear whether its products will end up having a viable commercial market of any scale. Meanwhile, research and development costs will continue to mount up.

Could the Scancell share price keep soaring?

So putting money into Scancell shares right now is investing in the hope of clinical trial success and commercialisation. In reality I do not think investors are able to tell the likelihood of such success until trial results are published.

If good news comes through, in the form of successful trial results, more licensing deals or a takeover bid by a bigger pharma rival, I think Scancell shares could rocket in 2023. But equally, if there is disappointing news from a trial, the Scancell share price could crash.

This strikes me more as speculation than investment. I have no way to know how efficacious Scancell’s products will turn out to be. So I have no basis on which to assess the company’s prospects. I am therefore not investing in it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

C Ruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »

Investing Articles

Why I’ve just sold two of the largest investments in my Stocks and Shares ISA

Stephen Wright has been making room for a new addition to his Stocks and Shares ISA. What is it and…

Read more »

Investing Articles

2 UK shares I’m avoiding like the plague in today’s stock market

Stephen Wright is a big fan of UK shares. But both the FTSE 100 and the FTSE 250 contain companies…

Read more »

Investing Articles

Down 13.7% in 7 days, what’s going on with the Lloyds share price?

Our writer looks at recent movements in the Lloyds share price. And asks whether now could be a good time…

Read more »